LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,488,736 entitled “Thienopyridinone Compounds and Methods of Treatment” to EPIX. The granted claims of this patent are directed to the highly selective 5-HT4 small molecule agonist, PRX-03140, and to compositions that include PRX-03140 as one of the active ingredients. EPIX also has pending patent applications relating to compositions and methods of using PRX-03140.
